Navigation Links
MIGENIX Third Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
Date:3/11/2008

Thursday, March 13, 2008 - 11:00 a.m. ET; 8:00 a.m. PT

VANCOUVER and SAN DIEGO, March 11 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, will host a conference call and webcast on Thursday, March 13, 2008 at 11:00 a.m. ET (8:00 a.m. PT) to discuss financial results for the third fiscal quarter ended January 31, 2008 and provide an update on company activities. To participate in the conference call, please dial 416-644-3417 or 1-800-732-0232. The call will be available for replay until March 27, 2008 by calling 416-640-1917 or 1-877-289-8525 and entering the pass code 21263848 followed by the number sign. The live and archived webcast can be accessed through the company's website at http://www.migenix.com for the next 90 days.

About MIGENIX

MIGENIX is committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs primarily in the area of infectious diseases. The Company's programs include drug candidates for: the prevention of catheter-related infections (Phase III), the treatment of chronic hepatitis C infections (Phase II and preclinical), the treatment of dermatological diseases (end of Phase II), the treatment of serious gram positive bacterial infections (preclinical) and the treatment of hepatitis B infections (preclinical). MIGENIX is headquartered in Vancouver, British Columbia, Canada with US operations in San Diego, California. Additional information can be found at http://www.migenix.com.

"Jim DeMesa"

James M. DeMesa, M.D.

President & CEO

CONTACT: Art Ayres, MIGENIX Inc., Tel: (604) 221-9666, Ext. 233, aayres@migenix.com; Dian Griesel, Ph.D., Investor Relations Group, Tel: (212) 825-3210, Theproteam@aol.com


'/>"/>
SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. MIGENIX releases CEO message #22
2. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
3. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
4. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
5. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
7. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
8. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
9. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. NeoStem to Present at Third Annual Stem Cell Summit in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... 2016 - And Other Rising ... of Those Competitor Biologics  - Biosimilar Drug ... Prospects ,  Who are the most important ... are their sales potentials? Discover, in our updated survey, ... opportunities and revenue forecasting. Visiongain,s ...
(Date:5/2/2016)... May 2, 2016 Q BioMed ... technology partner Mannin Research Inc. will be attending the ... takes place from May 1-5, 2016 in ... meeting with its vendors and research partners. The meeting ... goals and other collaborative opportunities for the MAN-01 program ...
(Date:4/29/2016)... Como, Italy (PRWEB) , ... April 30, 2016 , ... ... their extraordinary textile design, the bioLogic team explored how bacterial properties can be applied ... ways of using Natto bacteria, which move in response to humidity change. The team ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... necessary fundamentals to transform technology into a viable company, CereScan’s CEO, John Kelley, ... Mr. Kelley, a recognized leader and mentor in the Denver area business community, ...
Breaking Biology Technology:
(Date:3/15/2016)... -- Yissum Research Development Company of the Hebrew ... Hebrew University, announced today the formation of Neteera ... human biological indicators. Neteera Technologies has completed its first ... ... emissions from sweat ducts, enables reliable and speedy biometric ...
(Date:3/11/2016)... 11, 2016 --> ... report "Image Recognition Market by Technology (Pattern Recognition), by ... by Deployment Type (On-Premises and Cloud), by Industry Vertical ... by MarketsandMarkets, the global market is expected to grow ... Billion by 2020, at a CAGR of 19.1%. ...
(Date:3/9/2016)... Germany , March 9, 2016 ... country,s government identified that more than 23,000 public service ... or had been receiving their salary unlawfully.    ... African country,s government identified that more than 23,000 public ... name or had been receiving their salary unlawfully.    ...
Breaking Biology News(10 mins):